Study Summary
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express two chimeric antigen receptors (CARs). One is to recognize CD19 and the other is to recognize CD22, both of which are proteins expressed on the surface of the leukemic cell in patients with CD19+CD22+ leukemia. The CAR enables the T-cell to recognize and kill the leukemic cell through recognition of CD19 and CD22. This is a phase 1 study designed to determine the safety of the CAR+ T-cells and the feasibility of making enough to treat patients with CD19+CD22+ leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | United States |
| Children's National Medical Center | Washington D.C. | District of Columbia | United States |
| Riley Hospital for Children | Indianapolis | Indiana | United States |
| Seattle Children's Hospital | Seattle | Washington | United States |
| Children's and Women's Health Centre of British Columbia | Vancouver | British Columbia | Canada |